allogeneic cd123car-cd28-cd3zeta-egfrt-expressing t-lymphocytes
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02159495)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- allogeneic cd123car-cd28-cd3zeta-egfrt-expressing t-lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02159495 | Phase 1 | Dec 1, 2015 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1